IQVIA™ Real-World Insights Bibliography

The Certainty Framework for Assessing Real?World Data in Studies of Medical Product Safety and Effectiveness
Author(s): Noelle M. Cocoros Peter Arlett Nancy A. Dreyer Chieko Ishiguro Solomon Iyasu Miriam Sturkenboom Wei Zhou Sengwee Toh
Affiliations(s): 1Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA. 2Data Analytics and Methods Task Force, European Medicines Agency, Amsterdam, The Netherlands. 3London School of Hygiene and Tropic Medicine, London, UK. 4Center for Advanced Evidence Generation, IQVIA Real World Solutions, Cambridge, Massachusetts, USA. 5Division of Epidemiology, Office of Medical Informatics and Epidemiology, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan. 6Center for Observational and Real-world Evidence, Merck & Co., Inc., Kenilworth, New Jersey, USA. 7Julius Center, Global Health, University Medical Center Utrecht, Utrecht, The Netherlands.
Publication(s):  https://doi.org/10.1002/cpt.2045
Document Type(s): Article,
Countries: Japan, Netherlands, USA,
Click here for the abstract
C:
Y:
Health status & patient reported outcomes,
2020
  L:
A:
English
direct to patient research, Real World Data, Real World Evidence,
  Add to report
 
 
Cost effectiveness of cladribine tablets for treatment of RRMS in the Netherlands
Author(s): de Francesco M1, Mahajan K2, Michels RE3, Schiffers K4, Budhia S5, Harty G6, Krol M3
Affiliations(s): 1IQVIA, Zaventem, Belgium, 2IQVIA, Gurgaon, India, 3IQVIA, Amsterdam, The Netherlands, 4Merck B.V., an affiliate of Merck KGaA, Schiphol-Rijk, The Netherlands, 5PAREXEL International, Waltham, MA, USA, 6EMD Serono, Billerica, MA, USA
Publication(s):  2018-11, ISPOR Europe 2018, Barcelona, Spain
Document Type(s): Article,
Countries: Netherlands,
Click here for the abstract
C:
Y:
Neurological disorders,
2019
  L:
A:
English
Cost effectiveness, Predictive analytics,
  Add to report
 
 
Dutch health state utilities for infertility and subfertility.
Author(s): Krol M, Nap A, Michels RM, Veraart CPWM, Goossens LMA
Affiliations(s): IQVIA, Netherlands
Publication(s):  ISPOR 21st Annual European Congress, 2018, November 10-14, Barcelona, Spain
Document Type(s): Abstract,
Countries: Netherlands,
C:
Y:
Health economics, Health status & patient reported outcomes,
2018
  L:
A:
English
Quality of life, Utility analysis,
  Add to report
 
 
Cost effectiveness of cladribine tablets for treatmetn of RMS in The Netherlands.
Author(s): De Francesco M1, Mahajan K2, Michels R3, Schiffers K4, Budhia S5, Harty G5, Krol M3
Affiliations(s): 1 IQVIA, Zaventem, Belgium 2 IQVIA, India Michels 3 IQVIA, Netherlands 4 Merck, Netherlands 5 Merck, UK
Publication(s):  ISPOR 21st Annual European Congress, 2018, November 10-14, Barcelona, Spain
Document Type(s): Abstract,
Countries: Netherlands,
C:
Y:
Neurological disorders,
2018
  L:
A:
English
Cost effectiveness, Cost utility,
  Add to report
 
 
Healthcare utilization and costs of multiple sclerosis patients in the Netherlands: a healthcare claims database study.
Author(s): Buijs S1, Krol M2, de Voer G3
Affiliations(s): 1 Healthcare Insights, Netherlands 2 IQVIA, Netherlands 3 Merck, Netherlands
Publication(s):  Journal of Comparative Effectiveness Research, 2018, Vol. 7, No. 5
Document Type(s): Article,
Countries: Netherlands,
Click here for the abstract
C:
Y:
Neurological disorders,
2018
  L:
A:
English
Cost of illness,
  Add to report
 
 
TREATMENT AND DOSING PATTERNS AMONG PATIENTS WITH TYPE 2 DIABETES (T2D) INITIATING GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1 RAS) IN SEVERAL COUNTRIES
Author(s): Norrbacka K, Divino V, Boye K, Lebrec J, Dekoven M
Affiliations(s): Eli Lilly, IQVIA
Publication(s):  ISPOR Europe 2018
Document Type(s): Poster,
Countries: Belgium, Canada, France, Germany, Italy, Netherlands,
Click here for the abstract
C:
Y:
Diabetes,
2018
  L:
A:
English
Retrospective database analysis,
  Add to report
 
 
Direct and Indirect Protection with Pediatric Quadrivalent Live-Attenuated Influenza Vaccination in Europe Estimated by a Dynamic Transmission Model
Author(s): Gerlier L1, Hackett J2, Lawson R2, Dos Santos Mendes S3, Weil-Olivier C4, Schwehm M5, Eichner M6,7
Affiliations(s): 1 QuintilesIMS, Real-World Evidence Solutions, Zaventem, Belgium 2 AstraZeneca, Gaithersburg, MD, USA 3 AstraZeneca, Brussels, Belgium (Current affiliation: MSD, Brussels, Belgium) 4 Department of Pediatrics, University Paris VII, Paris, France 5 ExploSYS GmbH, Leinfelden-Echterdingen, Germany 6 Institute for Clinical Epidemiology and Applied Biometry, University of Tübingen, Tübingen, Germany 7 Epimos GmbH, Dusslingen, Germany
Publication(s):  JHEOR 2017;5(1):89-108
Document Type(s): Article,
Countries: Australia, Belgium, Finland, France, Germany, Greece, Italy, Luxembourg, Netherlands, Poland, Portugal, Spain, Sweden, UK,
C:
Y:
Immunology and Vaccination, Infectious disease, Respiratory disease,
2017
  L:
A:
English
Epidemiological study, Public Health,
  Add to report
 
 
Patient adherence to subcutaneous IFN beta-1a injections using the Rebismart® injection device:a retrospective real-world among Dutch and German patients with multiple sclerosis.
Author(s): Krol M1, deVoer G2, Osowski U3
Affiliations(s): 1 QuintilesIMS, The Netherlands 2 Merck B.V., Schiphol-Rijk, the Netherlands 3 Merck KGaA, Darmstadt, Germany
Publication(s): 
Document Type(s): Article,
Countries: Germany, Netherlands,
Click here for the abstract
C:
Y:
Neurological disorders,
2017
  L:
A:
English
clinical setting: Secondary care, Compliance, Retrospective database analysis,
  Add to report
 
 
Evaluation of the effectiveness of risk minimisation measures: a survey among health care professionals to assess their knowledge and attitudes on prescribing conditions of Instanyl® in France and the Netherlands.
Author(s): Toussi M1, Garofano A1, Jouaville L1, Bardoulat I1, Mitrofan L1
Affiliations(s): 1 QuintilesIMS, La Défense, France
Publication(s):  33rd International Conference on Pharmacoepidemiology & Therapeutic Risk Management, 2017, August 26-30, Montreal, Canada
Document Type(s): Poster,
Countries: France, Netherlands,
C:
Y:
Drug safety, Pain, Risk Management & REMS,
2017
  L:
A:
English
Clinical setting: hospital, Clinical setting: Primary care, clinical setting: Secondary care, Public Health, Survey research,
  Add to report
 
 
SCHÉMAS THÉRAPEUTIQUES ET POSOLOGIQUES CHEZ DES PATIENTS AVEC UN DIABÈTE DE TYPE 2 (DT2) INITIANT UN TRAITEMENT PAR AGONISTE DU RÉCEPTEUR DU GLUCAGON-LIKE PEPTIDE 1 (AR GLP-1) EN EUROPE
Author(s): Norrbacka K, Divino V, Dekoven M, Boye KS
Affiliations(s): Eli Lilly, IQVIA
Publication(s):  Societé Francophone du Diabete 2017
Document Type(s): Poster,
Countries: Belgium, Canada, France, Germany, Italy, Netherlands,
Click here for the abstract
C:
Y:
Diabetes,
2017
  L:
A:
English
Retrospective database analysis,
  Add to report
 
 
 1 of 5 Next Page Last Page